Through the drug-eluting stent labyrinth

Italian Heart Journal

Volumn 4, Issue 4, 2003, Pages 236-245

  Guagliumi, Giulio ^a   Musumeci, Giuseppe ^a   Vassileva, Angelina ^a   Tespili, Maurizio ^a   Valsecchi, Orazio ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Coronary angioplasty; Coronary artery disease; Restenosis; Stents

Indexed keywords

ANTIMITOTIC AGENT; DACTINOMYCIN; PACLITAXEL; RAPAMYCIN;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL STUDY; CONTROLLED RELEASE FORMULATION; CORONARY ARTERY ANEURYSM; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELUTION; HEALTH CARE COST; HEART MUSCLE ISCHEMIA; HUMAN; INTRACARDIAC THROMBOSIS; MATERIAL COATING; PATIENT CARE; PATIENT SELECTION; PROSPECTIVE STUDY; RESTENOSIS; SAFETY; SURGICAL TECHNIQUE; TREATMENT INDICATION; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTINEOPLASTIC AGENTS, PHYTOGENIC; COATED MATERIALS, BIOCOMPATIBLE; CORONARY DISEASE; CORONARY RESTENOSIS; COSTS AND COST ANALYSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS; SIROLIMUS; STENTS;

EID: 0037559757     PISSN: 1129471X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Faxon DP. Identifying the predictors of restenosis. Do we need new glasses? Circulation 1997; 95: 2244-6.
2. Morice MC, Serruys PW, Sousa JE, et al, for the RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-80.
3. Mintz GS, Popma JJ, Hong MK, et al. Intravascular ultrasound to discern device-specific effects and mechanisms of restenosis. Am J Cardiol 1996; 78 (3A): 18-22.
4. Kastrati A, Schomig A, Elezi S, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997; 30: 1428-36.
5. Bauters C, Hubert E, Prat A, et al. Predictors of restenosis after coronary stent implantation. J Am Coll Cardiol 1998; 31: 1291-8.
6. Serruys PW, van Hout B, Bonnier H, et al. Randomized comparison of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (BENESTENT II). Lancet 1998; 352: 673-81.
7. The ERASER Investigators. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation 1999; 100: 799-806.
8. Lee CW, Chae JK, Lim HY, et al. Prospective randomized trial of corticosteroids for the prevention of restenosis after intracoronary stent implantation. Am Heart J 1999; 138 (Part 1): 60-3.
9. Holmes D, Savage M, LaBlanche JM, et al. Results of Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) Trial. Circulation 2002; 106: 1243-50.
10. Hwang C, Wu D, Edelman ER. Physiological Transport Forces Govern Drug Distribution for Stent-Based Delivery. Circulation 2001; 104: 600-5.
11. Peng T, Gibula P, Yao KD, Goosen MF. Role of polymers in improving the results of stenting in coronary arteries. Biomaterials 1996; 17: 685-94.
12. Van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996; 94: 1690-7.
13. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995; 76: 412-7.
14. Zohlnhofer D, Klein C, Richter T, et al. Gene expression profiling of human stent-induced neointima by cDNA array analysis of microscopic specimens retrieved by helix cutter atherectomy: detection of FK506-binding protein 12 upregulation. Circulation 2001; 103: 1396-402.
15. Sirolimus-eluting stent recommended for approval by unanimous vote. http://www.theheart.org, heartwire, October 23, 2002.
16. Sousa JE, Abizaid A, Abizaid A, et al. Late (three-year) follow-up from the First-in-Man (FIM) experience after implantation of sirolimus-eluting stents. (abstr) Circulation 2002; 106: II-394.
17. Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 2001; 104: 2007-11.
18. Serruys PW, Degertekin M, Tanabe K, et al, for the RAVEL Study Group. Intravascular ultrasound findings in the multi-center, randomized, double-blind RAVEL (Randomized study with the sirolimus-eluting velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions) trial. Circulation 2002; 106: 798-803.
19. Schulen H, DirschingeT J, Kastrati A, et al. Effect of stent design and strut thickness on long-term outcome of coronary stent placement. Results from the ISAR STEREO II trial. (abstr) J Am Coll Cardiol 2002; 39 (Suppl A): I-22.
20. Popma J, Cox D, Farhat N, et al. Late angiographic and clinical findings after elective placement of the PENTA stent: results from the PENTA™ registry. (abstr) J Am Coll Cardiol 2002; 39 (Suppl A): II-1005.
21. Kereiakes D, Midei M, Hermiller J, et al. Procedural and late outcomes following multi-link DUET coronary stent deployment. Am J Cardiol 1999; 84: 1385-90.
22. de Jaegere P, Mudra H, Figulla H, et al. Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 month clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC study). Eur Heart J 1998; 19: 1214-23.
23. The Multi-Link VISION™ Stent Registry. QCA 180 Days Results. http://www.guidant.com
24. Moses JW, Leon MB, Popma JJ, et al. A multicenter randomized clinical study of the sirolimus-eluting stent in native coronary lesions: clinical outcomes. (abstr) Circulation 2002; 106: II-392.
25. Ako J, Morino Y, Honda Y. Serial stent edge analysis following sirolimus eluting stent implantation: interim IVUS Results from the SIRIUS Trial. (abstr) Circulation 2002; 106: II-519.
26. Leon M, Moses JW, Popma JJ, et al. A multicenter, randomized, clinical study of the sirolimus eluting stent in native coronary lesions: angiographic results. (abstr) Circulation 2002; 106: II-393.
27. Farb A, Heller PF, Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001; 104: 473-9.
28. Giannakakou P, Robey R, Fojo T, Blagosklonny MV. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene 2001; 20: 3806-13.
29. Gershlick AH, De Scheerder I, Chevalier B, et al. Local drug delivery to inhibit coronary artery restenosis: data from the ELUTES (Evaluation of Paclitaxel-Eluting Stent) clinical trial. (abstr) Circulation 2001; 104 (Suppl II): II-416.
30. Park SJ, Shim WH, Ho DS, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003; 348: 1537-45.
31. Guidant's paclitaxel-coated stent trial will not meet its primary end point. http://www.theheart.org, heartwire January 3, 2003.
32. Grube E, Silber SM, Eugene K, et al. TAXUS I: prospective, randomized, double-blind comparison of NIRx stents coated with paclitaxel in a polymer carrier in de-novo coronary lesions compared with uncoated controls. (abstr) Circulation 2001; 104 (Suppl II): II-463.
33. Grube E, Hauptmann K, Colombo A, et al. SCORE trial interim safety results: despite efficacy, late stent thrombosis with the QuaDDS-QP2 stent. (abstr) J Am Coll Cardiol 2002; 39: 38A.
34. Kataoka T, Grube E, Honda Y, et al. 7-Hexanoyltaxol-eluting stent for prevention of neointimal growth: an intravascular ultrasound analysis from the study to compare restenosis rate between QueST and QuaDS-QP2 (SCORE). Circulation 2002; 106: 1788-93.
35. Liistro F, Stankovic G, Di Mario C, et al. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation 2002; 105: 1883-6.
36. Virmani R, Liistro F, Stankovic G, et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate eluting polymer stent system in humans. Circulation 2002; 106: 2649-51.
37. Suzuki T, Kopia G, Hayashi S, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001; 104; 1188-93.
38. Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999; 99: 44-52.
39. Degertekin M, Regar E, Tanabe K, et al. Incidence of incomplete stent apposition at six-month follow-up in the multi center RAVEL trial. J Am Coll Cardiol 2002; 39 (Suppl A): 823-5.
40. Guagliumi G, Farb A, Musumeci G, et al. Sirolimus-eluting stent implanted in human coronary artery for 16 months: pathological findings. Circulation 2003; 107: 1340-1.